AUTHOR=Hecker Michael , Frahm Niklas , Bachmann Paula , Debus Jane Louisa , Haker Marie-Celine , Mashhadiakbar Pegah , Langhorst Silvan Elias , Baldt Julia , Streckenbach Barbara , Heidler Felicita , Zettl Uwe Klaus 

TITLE=Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.946351

DOI=10.3389/fphar.2022.946351

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Patients with multiple sclerosis (MS) often undergo complex treatment regimens, resulting in an increased risk of polypharmacy and potential drug-drug interactions (pDDIs). Drug interaction databases are useful for identifying pDDIs to support safer medication use.</p><p><bold>Objective:</bold> To compare three different screening tools regarding the detection and classification of pDDIs in a cohort of MS patients. Furthermore, we aimed at ascertaining sociodemographic and clinical factors that are associated with the occurrence of severe pDDIs.</p><p><bold>Methods:</bold> The databases Stockley’s, Drugs.com and MediQ were used to identify pDDIs by screening the medication schedules of 627 patients. We determined the overlap of the identified pDDIs and the level of agreement in pDDI severity ratings between the three databases. Logistic regression analyses were conducted to determine patient risk factors of having a severe pDDI.</p><p><bold>Results:</bold> The most different pDDIs were identified using MediQ (<italic>n</italic> = 1,161), followed by Drugs.com (<italic>n</italic> = 923) and Stockley’s (<italic>n</italic> = 706). The proportion of pDDIs classified as severe was much higher for Stockley’s (37.4%) than for Drugs.com (14.4%) and MediQ (0.9%). Overall, 1,684 different pDDIs were identified by at least one database, of which 318 pDDIs (18.9%) were detected with all three databases. Only 55 pDDIs (3.3%) have been reported with the same severity level across all databases. A total of 336 pDDIs were classified as severe (271 pDDIs by one database, 59 by two databases and 6 by three databases). Stockley’s and Drugs.com revealed 47 and 23 severe pDDIs, respectively, that were not included in the other databases. At least one severe pDDI was found for 35.2% of the patients. The most common severe pDDI was the combination of acetylsalicylic acid with enoxaparin, and citalopram was the drug most frequently involved in different severe pDDIs. The strongest predictors of having a severe pDDI were a greater number of drugs taken, an older age, living alone, a higher number of comorbidities and a lower educational level.</p><p><bold>Conclusions:</bold> The information on pDDIs are heterogeneous between the databases examined. More than one resource should be used in clinical practice to evaluate pDDIs. Regular medication reviews and exchange of information between treating physicians can help avoid severe pDDIs.</p>